Sutro Biopharma, Inc.

STRO

$20.38

-0.44%

2026-09-03 12:02:17 EDT-$0.09

Healthcare

Biotechnology

NASDAQ

Active Trading

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective ...

Price Action of STRO

$20.38

-0.44%-$0.09

High—

Low—

52W High-53.5%

Rel. vol—

Interval

Range6.3h

Volume—SMA5SMA10

—

Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2003 as Fundamental Applied Biology and renamed in 2009, the company is dedicated to transforming cancer treatment through its next-generation antibody-drug conjugate (ADC) platform. Sutro's proprietary XpressCF+ technology integrates cell-free protein synthesis ...Sutro Biopharma, Inc. (NASDAQ: STRO) is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2003 as Fundamental Applied Biology and renamed in 2009, the company is dedicated to transforming cancer treatment through its next-generation antibody-drug conjugate (ADC) platform. Sutro's proprietary XpressCF+ technology integrates cell-free protein synthesis with site-specific conjugation, enabling rapid and efficient production of homogeneous ADCs with optimized drug-to-antibody ratios and improved therapeutic windows. Sutro's pipeline includes two lead ADC candidates currently in Phase 1 clinical trials. STRO-001 targets CD74, an antigen highly expressed in multiple myeloma and non-Hodgkin lymphoma, and is designed to deliver a cytotoxic payload directly to cancer cells. STRO-002 targets folate receptor-alpha (FRα), which is overexpressed in ovarian and endometrial cancers, and has shown promise in early trials for these difficult-to-treat indications. Additionally, the company is advancing novel formats, such as dual-payload ADCs, to overcome tumor heterogeneity and combat drug resistance. Beyond its internal pipeline, Sutro has established strategic collaborations with major pharmaceutical companies. A partnership with Merck focuses on developing cytokine derivatives for oncology and autoimmune applications, while an agreement with Celgene (now Bristol-Myers Squibb) aims to identify bispecific antibodies and ADCs in immuno-oncology. These partnerships validate Sutro's platform and provide non-dilutive funding and potential milestone payments. Financially, as of the latest data (TTM), Sutro has a market capitalization of approximately $247 million. The company's revenue per share stands at $7.61, but it incurs significant research and development expenses (R&D to revenue ratio of 152%) and operating losses, leading to negative net income. However, with a strong cash position (cash per share of $15.48) and a healthy current ratio of 3.12, Sutro is well-capitalized to fund its clinical programs. The company employs 137 full-time staff, yet LinkedIn indicates a range of 201-500, possibly reflecting a broader base including contractors. Sutro has been recognized as a 'Best Place to Work' by BioSpace, highlighting its commitment to employee satisfaction and innovation. Under the leadership of CEO Jane Chung, who took office in March 2025, Sutro continues to advance its mission of delivering precisely designed cancer therapeutics. With a focus on unmet medical needs, robust partnerships, and a cutting-edge platform, Sutro Biopharma is positioned to make a significant impact in oncology and beyond.ExpandCollapse

Founded

2003

Employees

128

CEO

Jane Chung

Full Name

Sutro Biopharma, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

185.30%

Market Cap

$0.20B

Current Ratio

3.32

WACC

30.79%

ROIC

-100.73%

Contact Information

https://www.sutrobio.com

650 881 6500

111 Oyster Point Boulevard, South San Francisco, CA 94080

Key Metrics of STRO

Snapshot

Latest / TTM · 6 periods

Market Cap

$197.23M

ROCE

-100.0%

EV / EBITDA

-1.15x

+6.3% YoY

FCF Yield

-73.3%

+108.7% YoY

Cash Conversion Cycle

-912.2d

Current Ratio

3.32

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of STRO

Profitability trend

Latest / TTM · 6 periods

Gross Margin

97.2%

Net Margin

-395.2%

P/E Ratio

-1.18x

n/a

Debt / Equity

-0.10

n/a

Current Ratio

3.32

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of STRO

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-1.66 · Revenue $13.61M · 3 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-1.55 · Revenue $13.59M · 4 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-8.03 · Revenue $49.89M · 7 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-2.02 · Revenue $8.58M · 1 analysts

Recent history

Aug 12, 2026
Q2 FY2026 · Results reported
EPS $-2.33 · Revenue $9.84M
View filing
May 14, 2026
Q1 FY2026 · Results reported
EPS $-2.94 · Revenue $14.52M
View filing
Mar 23, 2026
FY2025 · Annual results
EPS $-22.49 · Revenue $102.48M
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $-6.70 · Revenue $9.69M
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-1.40 · Revenue $63.74M
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $-9.10 · Revenue $17.40M
View filing

Financial Statements of STRO

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$102.5M	+65.2%	-32.3%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-191.1M	+16.0%	-0.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+92.9%	+5.1%	+9.6%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-102.4%	+73.4%	-49.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-186.5%	+49.1%	-47.8%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-178.9M	+8.1%	+9.4%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-174.6%	+44.3%	-33.7%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	-11.8%	-122.8%	+48.8%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	2.01x	-22.8%	+6.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$173.8M	-55.1%	-19.6%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-22.49 vs -17.81	-26.3%	-2.33 vs -2.19	-6.2%
Revenue Surprise	$102.5M vs $99.2M	+3.3%	$9.8M vs $12.0M	-17.7%

Insider Transactions of STRO

Acquisitions (A)

Since Jun 2, 2026

Disposals (D)

Since Jun 2, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jun 5, 2026	Wigginton Jon Marc	director	Stock Option (right to buy)	A	10,000	$26.09
Jun 5, 2026	Petree Daniel H	director	Stock Option (right to buy)	A	10,000	$26.09
Jun 5, 2026	PANEK JAMES P	director	Stock Option (right to buy)	A	10,000	$26.09
Jun 5, 2026	Lobacki Joseph M	director	Stock Option (right to buy)	A	10,000	$26.09
Jun 5, 2026	Jagpal Sukhi	director	Stock Option (right to buy)	A	10,000	$26.09

Leadership Team of STRO

9 executives

Name	Title	Compensation	Gender	Year Born	Status
Jane Chung	Chief Executive Officer & Director	USD 1,163,250	Female	1971	Active
Hans-Peter Gerber	Chief Scientific Officer	USD 771,350	—	1964	Active
Gregory K. Chow	Chief Financial Officer	USD 520,583	Male	1973	Active
David Pauling	Chief Administrative Officer & General Counsel	—	Male	1974	Active
Jonathan Fawcett DPHIL MBBS	VP & Head of Clinical Development	—	Male	—	Active
Regina Cheng	Vice President & Controller	—	Female	—	Active
James R. Swartz	Founder	—	—	—	Active
Kari E. Leetch	Senior VP and Head of People & Culture	—	Female	—	Active
Devendra Luhar	Senior Vice President of Technical Operations	—	Male	—	Active

Recent News of STRO

Benzinga8/12/2026Neutral

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.

GlobeNewsWire8/12/2026Neutral

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro's platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter ended June 30, 2026 and recent business highlights.

247 Wallst8/7/2026Neutral

Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More

Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money fast, including a dramatic target cut on Trade Desk and a fresh Buy on SpaceX as markets brace for next week's inflation data.

Defense World7/25/2026Neutral

Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO

Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 42.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,069,519 shares of the company's stock after purchasing an additional 321,137 shares during the

Historical Employee Count of STRO

Current

137

Change

-55.81%

Minimum

137

Maximum

310

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	137	10-K	Mar 23, 2026	View
Dec 31, 2024	310	10-K	Mar 13, 2025	View
Dec 31, 2023	302	10-K	Mar 25, 2024	View
Dec 31, 2022	278	10-K	Mar 30, 2023	View
Dec 31, 2021	224	10-K	Feb 28, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Sutro Biopharma, Inc.